EP2209482A4 - Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof - Google Patents

Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof

Info

Publication number
EP2209482A4
EP2209482A4 EP08836519.2A EP08836519A EP2209482A4 EP 2209482 A4 EP2209482 A4 EP 2209482A4 EP 08836519 A EP08836519 A EP 08836519A EP 2209482 A4 EP2209482 A4 EP 2209482A4
Authority
EP
European Patent Office
Prior art keywords
muscle
treatments
derived progenitor
skeletal muscle
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP08836519.2A
Other languages
German (de)
French (fr)
Other versions
EP2209482A2 (en
Inventor
Thomas Payne
Ryan Pruchnic
Ronald Jankowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP2209482A2 publication Critical patent/EP2209482A2/en
Publication of EP2209482A4 publication Critical patent/EP2209482A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
EP08836519.2A 2007-10-04 2008-10-03 Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof Pending EP2209482A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97745007P 2007-10-04 2007-10-04
PCT/US2008/011458 WO2009045506A2 (en) 2007-10-04 2008-10-03 Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof

Publications (2)

Publication Number Publication Date
EP2209482A2 EP2209482A2 (en) 2010-07-28
EP2209482A4 true EP2209482A4 (en) 2016-06-01

Family

ID=40526882

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08836519.2A Pending EP2209482A4 (en) 2007-10-04 2008-10-03 Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof

Country Status (5)

Country Link
EP (1) EP2209482A4 (en)
JP (2) JP5687059B2 (en)
AU (1) AU2008307519B9 (en)
CA (1) CA2701354C (en)
WO (1) WO2009045506A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1812800B (en) 2003-04-25 2013-01-16 匹兹堡大学 Muscle derived cells(mdc) for promoting and enhancing nerve repair and regeneration
CA2674795C (en) 2007-01-11 2016-08-23 University Of Pittsburgh Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same
US9199003B2 (en) 2008-08-18 2015-12-01 University of Pittsburgh—of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
WO2024115761A1 (en) 2022-12-01 2024-06-06 Universität Zürich Method of preparing a mass culture of muscle precursor cells (mpcs) and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012503A2 (en) * 2002-07-30 2004-02-12 Tigenix N.V. Compositions comprising muscle progenitor cells and uses thereof
US6866842B1 (en) * 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en) * 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5538722A (en) 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
WO1996039035A1 (en) * 1995-06-06 1996-12-12 Case Western Reserve University Myogenic differentiation of human mesenchymal stem cells
AU5159901A (en) * 2000-04-14 2001-10-30 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6866842B1 (en) * 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en) * 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
WO2004012503A2 (en) * 2002-07-30 2004-02-12 Tigenix N.V. Compositions comprising muscle progenitor cells and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALLEN: "Skeletal muscle satellite cell cultures", METHODS IN CELL BIOLOGY, 1 January 1997 (1997-01-01), pages 155 - 176, XP055640285, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/9379949> [retrieved on 20191107] *
BARI DE C ET AL: "Multipotent mesenchymal stem cells from adult human synovial membrane", ARTHRITIS & RHEUMATISM, WILEY, US, vol. 44, no. 8, 1 August 2001 (2001-08-01), pages 1928 - 1942, XP002266867, ISSN: 0004-3591, DOI: 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P *
JANKOWSKI RON J ET AL: "Flow cytometric characterization of myogenic cell populations obtained via the preplate technique: Potential for rapid isolation of muscle-derived stem cells", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 12, no. 6, 10 April 2001 (2001-04-10), pages 619 - 628, XP002183830, ISSN: 1043-0342, DOI: 10.1089/104303401300057306 *
LEE J-Y ET AL: "Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing", THE JOURNAL OF CELL BIOLOGY : JCB, THE ROCKEFELLER UNIVERSITY PRESS, US, vol. 150, no. 5, 4 September 2000 (2000-09-04), pages 1085 - 1099, XP002161665, ISSN: 0021-9525, DOI: 10.1083/JCB.150.5.1085 *
MENDELL J., KISSEL J.T.,AMATO A.A., ET AL: "MYOBLAST TRANSFER IN THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY", NEW ENGLAND J. MED., 1 January 1995 (1995-01-01), XP055358109, Retrieved from the Internet <URL:http://www.nejm.org/doi/pdf/10.1056/NEJM199509283331303> [retrieved on 20170325] *
MUSGRAVE D S ET AL: "Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2", JOURNAL OF BONE AND JOINT SURGERY. BRITISH VOLUME, LIVINGSTONE, LONDON, GB, vol. 84-B, no. 1, 1 January 2002 (2002-01-01), pages 120 - 127, XP009061807, ISSN: 0301-620X, DOI: 10.1302/0301-620X.84B1.11708 *
QU-PETERSEN Z ET AL: "Identification of a novel population of muscle stem cells in mice: Potential for muscle regeneration", THE JOURNAL OF CELL BIOLOGY : JCB, THE ROCKEFELLER UNIVERSITY PRESS, US, vol. 157, no. 5, 27 May 2002 (2002-05-27), pages 851 - 864, XP002302343, ISSN: 0021-9525, DOI: 10.1083/JCB.200108150 *
See also references of WO2009045506A2 *
STEWART J D ET AL: "Characterization of proliferating human skeletal muscle-derived cells in vitro: differential modulation of myoblast markers by TGF-beta2", JOURNAL OF CELLULAR PHYSIOLOGY, WILEY SUBSCRIPTION SERVICES, INC, US, vol. 196, no. 1, 1 July 2003 (2003-07-01), pages 70 - 78, XP002317537, ISSN: 0021-9541, DOI: 10.1002/JCP.10322 *
TREMBLAY J.P., MALOUN F., ROY R., HUARD J.P. ET AL.: "RESULTS OF A TRIPLE BLIND CLINICAL STUDY OF MYOBLAST TRANSPLANTATIONS WITHOUT IMMUNISUPPRESSIVE TREATMENT IN YOUNG BOYS DUCHENNE MUSCULAR DYSTROPHY", CELL TRANSPLANTATION, COGNIZANT COMMUNICATION CORPORATION, US, vol. 2, no. 2, 1 January 1993 (1993-01-01), pages 99 - 112, XP000571490, ISSN: 0963-6897 *

Also Published As

Publication number Publication date
WO2009045506A2 (en) 2009-04-09
AU2008307519B2 (en) 2014-10-02
JP2010540639A (en) 2010-12-24
JP2014040485A (en) 2014-03-06
CA2701354C (en) 2018-07-24
AU2008307519B9 (en) 2014-11-13
CA2701354A1 (en) 2009-04-09
AU2008307519A1 (en) 2009-04-09
EP2209482A2 (en) 2010-07-28
JP5687059B2 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
TWI347842B (en) Tricyclic compounds, compositions, and methods
HK1155069A1 (en) Oil-in-oil type cosmetic composition
HK1146235A1 (en) Powder cosmetic composition
PL2245032T3 (en) Folates, compositions and uses thereof
LT2315773T (en) Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
PL2190405T5 (en) Hair treatment compositions
GB0706077D0 (en) Methods, Compositions and uses thereof
PL2150610T3 (en) Biofertilizer formulation
HK1145511A1 (en) Bactericidal cleanser composition
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
IL210498A0 (en) Nitrogen-containing aromatic heterocyclyl compounds, compositions comprising the same and uses thereof
IL207639A0 (en) Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof
EP2351553A4 (en) Cleanser composition
GB0809912D0 (en) Novel compositions and uses thereof
EP2209482A4 (en) Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
EP2170387A4 (en) Anti- mcp-1 antibodies, compositions, methods and uses
GB0715428D0 (en) Compositions and uses thereof
EP2328596A4 (en) Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
GB0701170D0 (en) Compositions and uses thereof
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
EP2356973A4 (en) Cosmetic composition
GB0701171D0 (en) Compositions and uses thereof
IL207174A0 (en) Peptides, compositions, and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB2480016B (en) Mixtures,compositions and methods of applying mixtures as coatings

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100504

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20090409

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYST

A4 Supplementary search report drawn up and despatched

Effective date: 20160429

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/34 20060101AFI20160422BHEP

Ipc: A61K 35/12 20060101ALI20160422BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170329

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION